Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Rx migraine indication a headache for OTCs?

This article was originally published in The Tan Sheet

  • News

Executive Summary

Ortho-McNeil receives FDA approval Aug. 11 for supplemental migraine headache prevention indication in adults for its anti-convulsant Topamax (topiramate). The approval of the J&J subsidiary's pain reliever will mean additional prescription competition for OTC migraine and headache marketers, who currently face off against GlaxoSmithKline's migraine drug Imitrex (sumatriptan) and Pfizer's Relpax (eletriptan)...

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

Industry Slates Decision To Exempt Parallel Importers From New Danish Stockpile Rules

Asian Industry Groups Push For Universal Care, E-Labeling, Flexible Supply Chain

See All
UsernamePublicRestriction

Register

PS097180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By